Glauser 2008.

Methods	Double‐blind, randomised, placebo‐controlled trial
Participants	Total randomised: 138 Age range of patients = 4 to 30 The patients were all diagnosed with Lennox‐Gastaut syndrome. No specific mention of the level of intellectual disability was made. The patients had a minimum of 90 seizures in the month. They were on 1 to 3 fixed‐dose regimens of 1 to 3 concomitant AEDs. Baseline period = 28 days. Treatment period = 84 days (14 days titration + 17 days treatment)
Interventions	Rufinamide versus placebo
Outcomes	Primary = reduction in total seizure frequency, tonic‐atonic ("drop attack") seizure frequency and seizure severity rating Secondary = response to treatment (% of patient with at least 50% reduction in seizure frequency during the double‐blind phase); % change in seizure frequency per 28 days relative to baseline (for each seizure subtype other than tonic‐atonic); parental global evaluation (alertness, interaction with environment, daily activity performance, responsiveness to verbal request and seizure severity)
Notes	Number used in data analysis 138
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information about how randomisation was achieved
Allocation concealment (selection bias)	Low risk	Numbers assigned to identical drugs
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Participants and study personnel blinded by use of identical drugs
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Outcome assessors were blinded
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comparable dropout rates across the groups. Intention‐to‐treat analysis carried out
Selective reporting (reporting bias)	Unclear risk	Protocol unavailable
Other bias	Unclear risk	No information about how trial was funded but no other evidence to suggest unclear risk of bias